board-directors-jeppe-8.html
Novo Annual Report 2015
9 / 72
steen riisgaard
board
member steen riisgaard was born on 22 march 1951 and is a danish national. he holds an msc in microbiology from the university of copenhagen. steen riisgaard was president and ceo of novo
zymes a/s from the demerger from novo nordisk a/s in 2000 until april 2013. he joined novo nordisk in 1979 in enzymes research & development. in 1982, he moved to tokyo to start up an enzymes r&d unit in the novo nordisk subsidiary, novo industri japan ltd. after his return to denmark in 1985, he held a number of different positions in the company, before he was promoted to corporate executive vice president in 1989 ? with special responsibility for the enzyme business. prior to joining novo nordisk, steen riisgaard was a research fellow at statens serum institut (ssi) and a research microbiologist at foss electric, denmark. steen riisgaard is chairman of the board of directors of alk-abello a/s, cowi holding a/s, egmont international holding a/s, xellia pharmaceuticals a/s and the world wildlife fund, denmark. furthermore, he is vice chairman of the boards of the novo nordisk foundation and the villum foundation, and serves on the boards of aarhus university, corbion nv and vkr holding. per wold-olsen board member per wold-olsen was born on 6 november 1947 and is a norwegian national. he holds an mba in economics and administration from the norwegian school of management in 1972, and an mba in management and marketing from the university of wisconsin, us, in 1973. per wold-olsen joined merck & co. (msd) in 1974. he became managing director of the norwegian subsidiary in 1976 and regional director and vice president of the scandinavian region in 1986. in 1991, per wold-olsen was appointed senior vice president for worldwide human health marketing of merck & co. inc. in the us, and in 1994, he was appointed president of human health europe of merck & co., inc. in 1997, his region increased to include eastern europe, the middle east and africa, as well as worldwide human health marketing. in 2005, he was appointed president of the human health intercontinental region, merck & co. inc. from 1994 to 2006, he was also a member of merck?s management committee. per wold-olsen is chairman of the board of directors of gn store nord a/s and medicines for malaria venture, and serves on the board of directors of exiqon a/s and gilead sciences inc. eivind kolding
ceo eivind kolding was born on 16 november 1959 and is a danish national. he holds an ma degree in law from the university of copenhagen and was admitted lawyer to the bar in 1986 and the high courts in 1988. in 1989, eivind kolding joined the a.p. moller-maersk group. during his 22 years with the company he held a number of different positions. from 1991 to 1995, he served as head of corporate secretariat, a.p. møller-mærsk a/s; from 1996 to 1998, he was managing director of maersk hong kong ltd.; and from 1998 to 2006, he served as cfo of the a.p. moller- maersk group. finally, from 2006 to 2011, he became partner and ceo of maersk line. in 2001, eivind kolding joined the board of danske bank, became vice chairman of the board in 2005 and its chairman in 2011. from 2012 to 2013, he served as group ceo of danske bank. eivind kolding serves on the boards of novo nordisk a/s, nnit a/s and the sonion group. eivind kolding resigned as ceo at the end of february, 2016. annual review 2015 9 board of directors and management
management-report-novo-10.html
